Gantenerumab

Summary

Gantenerumab (CHEMBL1743025) is a phase-3 clinical-stage antibody; indicated across 1 condition including alzheimer disease.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Antibody
• Indications: 1 condition
• Clinical trials: 18

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1743025
Name	Gantenerumab
Type	Antibody
Max phase	3

Also known as: Gantenerumab, R-04909832, R-1450, R04909832, R1450, RG-1450, RO-4909832 R-1450, Ro-4909832, GANTENERUMAB

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

1 indication (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
Alzheimer disease	3	MONDO:0004975	MONDO:0004975

Clinical trials

Total trials: 18.

Phase distribution

Phase	Trials
PHASE3	7
PHASE1	7
PHASE2/PHASE3	3
PHASE2	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT01760005	PHASE2/PHASE3	ACTIVE_NOT_RECRUITING	Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset Alzheimer’s Disease Caused by a Genetic Mutation. Master Protocol DIAN-TU-001
NCT01224106	PHASE3	COMPLETED	A Study of Gantenerumab in Participants With Prodromal Alzheimer’s Disease
NCT02051608	PHASE3	COMPLETED	A Study of Gantenerumab in Participants With Mild Alzheimer Disease
NCT03443973	PHASE3	TERMINATED	Safety and Efficacy Study of Gantenerumab in Participants With Early Alzheimer’s Disease (AD)
NCT03444870	PHASE3	TERMINATED	Efficacy and Safety Study of Gantenerumab in Participants With Early Alzheimer’s Disease (AD)
NCT04339413	PHASE3	TERMINATED	A Study to Evaluate the Safety and Tolerability of Long-term Administration of Gantenerumab in Participants With Alzheimer’s Disease (AD)
NCT04374253	PHASE3	TERMINATED	A Study to Evaluate the Safety, Tolerability, and Efficacy of Long-Term Gantenerumab Administration in Participants With Alzheimer’s Disease (AD)
NCT04623242	PHASE2/PHASE3	COMPLETED	Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset Alzheimer’s Disease Caused by a Genetic Mutation.
NCT05256134	PHASE3	TERMINATED	A Study to Evaluate the Efficacy and Safety of Gantenerumab in Participants at Risk for or at the Earliest Stages of Alzheimer’s Disease (AD)
NCT06424236	PHASE2/PHASE3	TERMINATED	Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia: A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset Alzheimer’s Disease Caused by a Genetic Mutation
NCT04592341	PHASE2	TERMINATED	A Study to Evaluate the Pharmacodynamic (PD) Effects of Once Weekly Administration of Gantenerumab in Participants With Early Alzheimer’s Disease (AD)
NCT00531804	PHASE1	COMPLETED	A Multiple Ascending Dose Study of R1450 in Patients With Alzheimer Disease.
NCT01636531	PHASE1	COMPLETED	A Study of A High Concentration Liquid Formulation Versus A Lyophilized Formulation of Gantenerumab in Healthy Volunteers
NCT01656525	PHASE1	COMPLETED	A Multiple-dose Study of Gantenerumab in Japanese Alzheimer’s Disease Patients
NCT02133937	PHASE1	COMPLETED	A Study Investigating the Bioavailability of a High Concentration Liquid Formulation Versus a Reference Lyophilized Formulation of Gantenerumab in Healthy Volunteers
NCT02711423	PHASE1	COMPLETED	A Single-Dose Study to Investigate the Safety, Tolerability, and Pharmacokinetics (PK) of Gantenerumab Following Subcutaneous (SC) Administration in Healthy Volunteers
NCT02882009	PHASE1	COMPLETED	A Study to Assess the Impact of Speed and Site of Subcutaneous Injection on Pain, Tolerability, Safety, and Pharmacokinetics of Gantenerumab in Healthy Participants
NCT03236844	PHASE1	COMPLETED	Relative Bioavailability of Gantenerumab Produced by G4 Process Versus G3 Process Following Subcutaneous (SC) Injection in Healthy Participants

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).